Effect of antiviral treatments on the bone marrow in murine aids.
Blood cytopenia is a common feature in HIV infection, occurring in up to 70% of patients with AIDS. Since at present it is not clear to what extent this is intrinsic to HIV infection or due to opportunistic infections and antiretroviral agents we have investigated the long-term effects of conventional and new antiviral drugs on the bone marrow of normal and immunodeficient mice. The results show that azidothymidine (AZT), dideoxycytidine (DDC) and dideoxycytidine 5'-triphosphate (DDCTP) alone or in combination are all effective in inhibiting the expression of the retroviral protein Pr60gag in bone marrow cells. However, DDCTP was the most effective in preventing bone marrow cytopenia. Combined treatments of AZT plus DDCTP result in a reduction in erythroid precursors compared to that resulting from DDCTP administration, while DDC plus DDCTP results in a differential cell count similar to that found in uninfected mice. Thus, the bone marrow in murine AIDS may prove useful as a model for therapy of retroviral infections and for treating blood cytopenias.
Brandi
G
G
Istituto di Igiene, Università degli Studi di Urbino, Italy.
Carnevali
A
A
Rossi
L
L
Fraternale
A
A
Schiavano
G F
GF
Magnani
M
M
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D054306:Dideoxynucleotides; D015683:Gene Products, gag / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D016183:Murine Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism* / Q000821:virology; D013942:Thymine Nucleotides / Q000627:therapeutic use*; D016047:Zalcitabine / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
D000998:Antiviral Agents; D054306:Dideoxynucleotides; D015683:Gene Products, gag; D013942:Thymine Nucleotides; D015215:Zidovudine; D016047:Zalcitabine; C017216:2',3'-dideoxythymidine triphosphate